The following presentations were given at the Plenary Session of the Spring 2009 Group Meeting in San Francisco, "Future Directions of the Southwest Oncology Group and 2009 Abstract Showcase." To view these videos, JavaScript must be enabled in your browser, and it must have the Adobe Flash Player plugin; if it does not, the program can install it for you. We suggest setting the audio volume on your computer to a moderate level before you begin. Note: These presentations are multi-megabyte in size, so will take as much as a few minutes to initially buffer, even on a fast connection. Please be patient.

Friday, April 24, 2009
Southwest Oncology Group Competitive Renewal: Site Visit Presentation Laurence H. Baker, D.O. Chair, Southwest Oncology Group
Oxaliplatin Plus Protracted Infusion 5-Fluorouracil and External Beam Radiation Prior to Surgery for Potentially Curable Esophageal Adenocarcinoma: A SWOG Phase II Trial with Molecular Correlates (S0356) Lawrence P. Leichman, M.D. Director, GI Cancer Research Aptium Oncology; and Director, Aptium Oncology GI Cancer Consortium (AGICC)Comprehensive Cancer Center Desert Regional Medical Center, Palm Springs, CA
	Discussant Peter Enzinger, M.D. Clinical Director, GI Cancer Center, Dana Farber Cancer Institute; and Assistant Professor of Medicine, Harvard Medical School, Boston, MA
Chemoradiation of Resected Gastric Cancer: A 10 Year Follow-up of the Phase III Trial INT0116 (SWOG 9008) John S. Macdonald, M.D., F.A.C.P., Chief Medical Officer, Aptium Oncology Inc., Los Angeles, CA
	Discussant Peter Enzinger, M.D. Clinical Director, GI Cancer Center, Dana Farber Cancer Institute; and Assistant Professor of Medicine, Harvard Medical School, Boston, MA
Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma Lisa Rimsza, M.D. Professor of Pathology, Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson Chair, SWOG Lymphoma Translational Medicine Subcommittee; and Vice Chair, SWOG Translational Medicine Committee
	Discussant Thomas Miller, M.D. Professor of Medicine, Chief, Section of Hematology/Oncology, Director, Lymphoma Program,Department of Medicine, Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson SWOG, Vice Chair, Lymphoma committee
Communicating the Early End of Intervention to Participants in a Large Ongoing Study Jo Ann Hartline, M.P.H. Project Manager, SELECT SWOG Statistical Center, Seattle
	Discussant Gary Goodman, M.D. Staff Oncologist, Swedish Medical Center Cancer Institute and Joint Member, Hutchinson Cancer Research Center, Seattle
S0509: A Phase II Study of Novel Oral Anti-Angiogenic Agent AZD2171 in Malignant Pleural Mesothelioma Linda Garland, M.D. Associate Professor of Clinical Medicine, Director of Clinical Lung Cancer Program Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson
	Discussant Harvey Pass, M.D. Professor of Cardiothoracic Surgery and Surgery Director, Division of Thoracic Surgery and Thoracic Oncology Department of Cardiothoracic Surgery, New York University School of Medicine and Clinical Cancer Center, New York, NY